Freeline Therapeutics, the biopharmaceutical company that specializes in liver directed gene therapies, raised £88.4M in Series B funding led by Syncona Partners LLP and including participation from UCL Technology Fund, bringing the total funding amount to $155.9M over three rounds for the startup founded in 2015.
Page 11 of 15
